TroVax (MVA 5T4) / Oxford Biomedica 
Welcome,         Profile    Billing    Logout  
 38 Diseases   3 Trials   3 Trials   44 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TroVax (MVA 5T4) / Oxford Biomedica
2007-005639-26: A Multicenter, Double Blind, Placebo controlled, Randomized study of TroVax vs Placebo in the First Line treatment of Patients with Metastatic Colorectal Cancer receiving Chemo-based Therapy.

Ongoing
2/3
1312
Europe
TroVax, SAR109659, Powder for solution for injection
Oxford BioMedica, Oxford BioMedica (UK) Limited
Metastatic Colorectal Adenocarcinoma
 
 
2010-024380-41: A pilot study to assess the effect of regulatory T-cell depletion on 5T4-containing MVA(TroVax®)vaccination in patients with inoperable metastatic colorectal cancer

Ongoing
2
54
Europe
Cyclophosphamide Tablets, TroVax, Not applicable, Cyclophosphamide 50 Tablets, Cyclophosphamide 50 Tablets
Cardiff University
Inoperable metastatic colorectal cancer
 
 
2006-000753-22: A phase I/II feasability trial to assess the safety, immunological activity and efficacy of TroVax plus interferon alpha in patients with advanced or metastatic renal cell cancer.

Ongoing
1/2
10
Europe
TroVax, Roferon-A, TV, Roferon-A, Roferon-A
Oxford MioMedica UK Ltd.
Advanced or Metastatic Renal Cell Cancer
 
 

Download Options